Cancer Research Horizons
Cancer Research Horizons is a London-based organization dedicated to the development and commercialization of innovations in cancer research. Established in 1982, it serves as a critical connection between academia and industry, leveraging its deep understanding of both sectors to transform promising research into viable commercial solutions that benefit patients while maximizing financial returns. The organization is uniquely positioned to draw on the extensive research and partnerships fostered by its parent entity, Cancer Research UK, the leading charitable funder of cancer research globally. With over 30 years of specialized experience, Cancer Research Horizons has a proven track record in advancing cancer therapeutics, diagnostics, and related technologies. Its team, comprised of experienced and motivated professionals, is divided between drug discovery and commercialization, ensuring a comprehensive approach to delivering breakthrough therapies to patients.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
10 past transactions
52 North Health
Venture Round in 2024
52 North Health develops an AI-powered medical device for determining neutropenic sepsis risk in chemotherapy patients. Its portable finger-prick blood test measures neutrophil count and C-Reactive Protein (CRP) levels at home, enabling early detection and improved management of this fatal side effect.
Infinitopes
Seed Round in 2024
Infinitopes is a cancer research organization focused on immunotherapy to prevent metastasis and improve survival. The company develops a platform that combines efficient vector delivery with tumor target identification technologies to enable early-stage clinical trials and therapies designed to stop cancer before it spreads. Its cancer vaccine platform aims to prevent metastases by identifying tumor-specific peptides with high accuracy and delivering them through a durable viral vector, supporting post-surgical relapse prevention for esophageal cancer patients and advancing earlier, smarter immunotherapy. By integrating immune system strengthening and targeted peptide delivery, Infinitopes seeks to create treatments that intervene at early stages to reduce relapse and improve outcomes.
Neobe Therapeutics
Seed Round in 2024
Neobe Therapeutics provides immunotherapies, clinical trials, research, and tumor-colonizing bacteria engineering services.
Trogenix
Seed Round in 2024
Trogenix operates as a therapeutics company, that treats aggressive cancers.
NK:IO
Seed Round in 2023
NK:IO is a biotechnology company focused on developing natural killer cell-mediated immunotherapies for cancer. The company develops both cell therapies and small molecule therapeutics designed to target cancer and enhance the tumor-killing activity of natural killer cells.
Elaitra
Pre Seed Round in 2023
Elaitra develops AI-driven breast cancer diagnostic tools. Their platform includes a voice-based patient engagement system powered by Generative LLM and an AI reading tool for 3D X-rays, approved by FDA and UK regulators.
BioCaptiva
Seed Round in 2022
BioCaptiva develops innovative liquid biopsy technology devices aimed at diagnosing and monitoring hard-to-detect cancers. Its proprietary platform captures circulating free DNA from blood samples, overcoming current limitations of cancer liquid biopsy testing.
Achilles Therapeutics
Seed Round in 2016
Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, specializing in the development of patient-specific immunotherapies designed to combat cancer. Founded in 2016, the company focuses on personalized vaccines and T cell therapies that utilize the body's immune system to target and eliminate cancer cells. Achilles Therapeutics aims to identify and target truncal tumor neoantigens and other markers present on cancer cells, allowing for precise attacks on tumors while sparing healthy tissue. The company is currently conducting clinical trials, including the CHIRON trial for non-small-cell lung cancer and the THETIS trial for recurrent or metastatic melanoma, to evaluate the efficacy and safety of its innovative therapies.
GammaDelta Therapeutics
Seed Round in 2016
GammaDelta Therapeutics focuses on developing innovative immunotherapies utilizing gamma delta (γδ) T cells to treat cancer and autoimmune diseases. The company aims to harness the unique properties of tissue resident γδ T cells to enhance the effectiveness of immunotherapy. By leveraging these specialized immune cells, GammaDelta Therapeutics seeks to provide patients with improved treatment options that can significantly impact their health outcomes in the face of serious diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.